Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

The prognostic impact of achieving and in particular maintaining measurable residual disease (MRD) negativity in multiple myeloma is now established; therefore, identifying among MRDnegative patients the ones at higher risk of losing MRD negativity is of importance. We analyzed predictors of unsustained MRD negativity in patients enrolled in the FORTE trial (NCT02203643). MRD was performed by multiparameter flow cytometry (sensitivity of 10-5) at premaintenance and every 6 months thereafter. The cumulative incidence (CI) of MRD resurgence and/or progression was analyzed in MRD-negative patients. A total of 306 of 474 (65%) MRD-negative patients were analyzed. After a median follow-up of 50.4 months from MRD negativity, 185 of 306 (60%) patients were still MRD negative and progression free, 118 (39%) lost their MRD-negative status, and 3 patients (1%) died without progression. Amp1q vs normal (4 -year CI, 63% vs 34), 22 concomitant high -risk cytogenetic abnormalities vs 0 (4 -year CI, 59% vs 33%), circulating tumor cells at baseline (high vs low at 4 -year CI, 62% vs 32%), and time-to-reach MRD negativity postconsolidation vs preconsolidation (4 -year CI, 46% vs 35%) were associated with a higher risk of unsustained MRD negativity in a multivariate Fine -Gray model. During the first 2 years of maintenance, patients receiving carfilzomib-lenalidomide vs lenalidomide alone had a lower risk of unsustained MRD negativity (4 -year CI, 20% vs 33%).